SCHEMBL4675488

SCHEMBL4675488

Nc1ccc(Cc2csc(CC(=O)C(=O)c3nc[nH]n3)n2)cc1

nearest known ligand 0.39

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 3/20 0.39
HDAC6 Q9UBN7 3/20 0.39
AOC3 Q16853 3/20 0.31
MAOB P27338 2/20 0.31
L3MBTL1 Q9Y468 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4674614 0.91 HDAC1 (0.39) HDAC1HDAC6AOC3MAOB
SCHEMBL4672336 0.89 HDAC6 (0.39) HDAC1HDAC6L3MBTL1
SCHEMBL4671165 0.89 BCHE (0.39) L3MBTL1
SCHEMBL4676893 0.89 HDAC1 (0.42) HDAC1HDAC6L3MBTL1
SCHEMBL5899406 0.88 HDAC1 (0.32) HDAC1HDAC6
SCHEMBL4675409 0.87 KMT2A (0.37) HDAC1HDAC6AOC3MAOB
SCHEMBL5899379 0.87 HDAC1 (0.43) HDAC1HDAC6
SCHEMBL4675014 0.83 HDAC1 (0.39) HDAC1HDAC6AOC3MAOB
SCHEMBL4678623 0.81 HDAC1 (0.43) HDAC1HDAC6MAOB
SCHEMBL4671892 0.80 BCHE (0.37) HDAC1HDAC6L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 HDAC1 250/4885HDAC6 1000/4885AOC3 3344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.